terbogrel

Subscribe to Selected New Research on terbogrel

2 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: RN refers to (5E)-isomer

Also Known As:

(5E)-6-(m-(3-tert-Butyl-2-cyanoguanidino)phenyl)-6-(3-pyridyl)-5-hexenoic acid; 6-(3-(((cyanoamino)((1,1-dimethylethyl)amino)methylene)amino)phenyl)-6-(3-pyridinyl)hexenoic acid

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Pyridines: 26

terbogrel: 2

Experts

1.	Seeger, Werner: 1 article (05/2002)
2.	Higenbottam, Timothy W: 1 article (05/2002)
3.	Naeije, Robert: 1 article (05/2002)
4.	Dias, Virgil C: 1 article (05/2002)
5.	Kneussl, Meinhard: 1 article (05/2002)
6.	Oudiz, Ronald: 1 article (05/2002)
7.	Hirsch, Andrew M: 1 article (05/2002)
8.	Mehta, Sanjay: 1 article (05/2002)
9.	Riedel, Axel: 1 article (05/2002)
10.	Solèr, Markus: 1 article (05/2002)

Related Diseases

1.	Pain (Aches) 05/01/2002 - "RESULTS: Although the planned enrollment was 135 patients, the study was halted after only 71 patients had been randomized because of the unforeseen side effect of leg pain, which occurred almost exclusively in patients with terbogrel treatment" 05/01/2002 - "CONCLUSION: Inhibition of thromboxane with an orally active agent is feasible in PPH, but the incidence of severe leg pain with terbogrel precludes its use in this disorder" Get all the results and reference details, order at left...
2.	Pulmonary Hypertension (Ayerza Syndrome) 08/01/2005 - "Terbogrel may ameliorate pulmonary artery dysfunction and attenuate the development of chronic hypoxia-induced pulmonary hypertension in newborns." 08/01/2005 - "Our objective was to determine whether a combined thromboxane synthase inhibitor-receptor antagonist, terbogrel, prevents pulmonary hypertension and the development of aberrant pulmonary arterial responses in newborn piglets exposed to 3 days of hypoxia" 05/01/2002 - "Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension." Get all the results and reference details, order at left...
3.	Anoxia (Hypoxia) 08/01/2005 - "Terbogrel may ameliorate pulmonary artery dysfunction and attenuate the development of chronic hypoxia-induced pulmonary hypertension in newborns." 08/01/2005 - "Our objective was to determine whether a combined thromboxane synthase inhibitor-receptor antagonist, terbogrel, prevents pulmonary hypertension and the development of aberrant pulmonary arterial responses in newborn piglets exposed to 3 days of hypoxia" Get all the results and reference details, order at left...
3 Diseases and 2 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Thromboxane-A Synthase
1 Drugs and Important Bio-Agents and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>